Outcomes After Transcatheter Aortic Valve Replacement Using a Novel Balloon-Expandable Transcatheter Heart Valve A Single-Center Experience by Husser, Oliver et al.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S VO L . 8 , N O . 1 4 , 2 0 1 5
ª 2 0 1 5 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N DA T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 5 . 0 8 . 0 1 4Outcomes After Transcatheter
Aortic Valve Replacement Using
a Novel Balloon-Expandable
Transcatheter Heart Valve
A Single-Center ExperienceOliver Husser, MD,* Costanza Pellegrini, MD,* Thorsten Kessler, MD,* Christof Burgdorf, MD,* Hannah Thaller,*
N. Patrick Mayr, MD,y Ilka Ott, MD,* Albert M. Kasel, MD,* Heribert Schunkert, MD,*z Adnan Kastrati, MD,*z
Christian Hengstenberg, MD*zABSTRACTFro
Mu
Mu
Re
Lif
Lif
to
MaOBJECTIVES Evaluation of 30-day outcomes after transcatheter aortic valve replacement (TAVR) with the novel
balloon-expandable SAPIEN 3 (S3) transcatheter heart valve (THV) (Edwards Lifesciences, Irvine, California) emphasizing
the updated Valve Academic Research Consortium (VARC-2) criteria.
BACKGROUND Preliminary data on clinical performance with the S3 THV are promising. However, information
regarding 30-day outcome is limited.
METHODS A total of 250 consecutive patients undergoing transfemoral TAVR with the S3 THV at our center were
enrolled, and outcomes according to VARC-2 criteria were analyzed at 30 days.
RESULTS The mean age was 81.0  6.2 years, median logistic EuroSCORE (European System for Cardiac Operative Risk
Evaluation) and Society of Thoracic Surgeons score were 12.1% and 4.4%, respectively. VARC-2–deﬁned device success
was achieved in 244 patients (97.6%); moderate paravalvular leakage developed in 5 patients (2.0%). One patient
(0.4%) died of a noncardiac cause and 8 patients (3.2%) had a stroke. Life-threatening bleeding and major vascular
complications occurred in 12 (4.8%) and 9 (3.6%) of the patients, respectively. From discharge to 30 days, 5 patients
(2.0%) were hospitalized due to valve-related symptoms or worsening of heart failure. The VARC-2 composite early
safety endpoint was observed in 25 patients (10.0%). Permanent pacemaker implantation rate at 30 days was 15.2%.
Myocardial infarction, coronary obstruction requiring intervention, valve-related dysfunction, and endocarditis were not
observed.
CONCLUSIONS We found very good 30-day results using the novel S3 THV with a low rate of clinical events according
to VARC-2 criteria. The S3 THV is associated with high procedural success and favorable early safety proﬁle. The need for
pacemaker implantations appears to be more frequent than with its predecessor. (J Am Coll Cardiol Intv 2015;8:1809–16)
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ABBR EV I A T I ON S
AND ACRONYMS
MSCT = Multislice computed
tomography
NYHA = New York Heart
Association
TAVR = transcatheter aortic
valve replacement
THV = transcatheter heart
valve
S3 = SAPIEN 3
VARC-2 = Valve Academic
Research Consortium
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1810T ranscatheter aortic valve replace-ment (TAVR) has rapidly evolvedfrom a novel technology to the
preferred treatment for patients with severe
symptomatic aortic stenosis who cannot un-
dergo conventional surgical aortic valve
replacement (1) and has been shown to be
noninferior in high-risk patients (2). Large
clinical registries have consistently reported
excellent outcomes (3–5) and decreased
complication rates (6).SEE PAGE 1817Although, in part, this decrease may be attributable
to increasing operator experience, the evolution of
TAVR with novel transcatheter heart valves (THVs)
and further iterations of delivery systems to reduce
periprocedural complications also play an important
part. Periprocedural complications include para-
valvular leakage, new permanent pacemaker im-
plantations, thromboembolic events, bleeding, and
vascular complications.
The SAPIEN 3 (S3) (Edwards Lifesciences, Irvine,
California) is a novel balloon-expandable THV
featuring a lower proﬁle delivery system (Comman-
der, Edwards Lifesciences) to reduce the risk of
vascular injury as well as access site complications
and allows for rapid and accurate positioning. Addi-
tionally, this device features a sealing cuff to reduce
paravalvular regurgitation (7). The S3 THV received
the CE mark in Germany in January 2014. To date,
only small series (8–10) and 1 modest-sized multi-
center trial (11) have assessed this novel device and
clinical efﬁcacy, and 30-day outcome is still unclear.
The upcoming ﬁnal results of the large-scale multi-
center PARTNER II Trial: Placement of Aortic Trans-
catheter Valves (12) are still eagerly awaited.
Here we report our single-center experience using
the S3 THV, according to the updated standardized
endpoint deﬁnitions issued by the Valve Academic
Research Consortium (VARC-2) (13) with special
emphasis on the composite early safety endpoint at
30 days.
METHODS
PATIENT POPULATION. Between January 2014 and
March 2015, 261 consecutive patients with severe
symptomatic aortic stenosis were treated with trans-
femoral TAVR using the S3 THV at the Department
of Cardiology, Deutsches Herzzentrum München,
Munich, Germany. Patients treated with other
devices or requiring valve-in-valve procedures due to
degenerated bioprostheses were excluded from theanalysis. Therefore, the ﬁnal study population con-
sisted of 250 patients. All cases were discussed by the
multidisciplinary heart team, and consensus was
achieved regarding the therapeutic strategy. TAVR
was performed in a hybrid operating suite with pa-
tients under general anesthesia or conscious seda-
tion. All patients provided written informed consent
for the procedure.
ECHOCARDIOGRAPHY AND MULTISLICE COMPUTED
TOMOGRAPHY DATA ANALYSIS. Transthoracic echo-
cardiography was performed before TAVR, before
discharge, and at the 30-day follow-up visit. Left
ventricular ejection fraction, mean transvalvular
gradient, and paravalvular regurgitation were deter-
mined. Discharge echocardiographic data were avail-
able for 242 patients, and 30-day echocardiographic
follow-up was available in 185 patients.
Multislice computed tomography (MSCT) was
performed as part of the standard pre-procedural
screening protocol. Aortic annulus measurements
were assessed in multiple plane reconstructions ac-
cording to the guidelines of the Society of Cardio-
vascular Computed Tomography (14). In short, the
area and perimeter of the virtual aortic annulus were
obtained by direct planimetry. The minimal and
maximal diameter were determined, and the effective
diameter was calculated as the sum of the minimal
and maximal diameter divided by 2. Calciﬁcation of
the valvular apparatus was assessed at the height of
the aortic cusps, annulus, and the left ventricular
outﬂow tract and visually graded as none, mild,
moderate, and severe. Dedicated U.S. Food and Drug
Administration–approved software (OsiriX MD 3.9.4,
Pixmeo, Switzerland) was used.
PROSTHESIS SIZE SELECTION AND PROCEDURE.
The technical features of the S3 THV have been
described elsewhere (7,11). The device is available in
23-, 26-, and 29-mm sizes. The dimensions of a
nominally expanded S3 THV and the manufacturer’s
sizing recommendations are given in Online Table 1.
The ﬁnal decision on prosthesis size was left to the
discretion of the physicians performing the procedure
based on MSCT measurements and taking into ac-
count other anatomic features such as the presence
and distribution of calciﬁcation, eccentricity of the
aortic annulus, and also the patient anatomy in case
of borderline sizing ranges.
The percentage of oversizing according to area was
calculated using the formula: (nominal prosthesis
dimension/patient anatomy  1)  100. The adher-
ence to the manufacturer’s sizing guidelines by area
was categorized as “undersized,” “within range,” and
“oversized.” The implantation plane was identiﬁed
TABLE 1 Baseline Characteristics: Total Patients (N ¼ 250)
Clinical characteristics
Age, yrs 81.0  6.2
Female 109 (43.6)
BMI, kg/m2 26.9  4.8
Logistic EuroSCORE I, % 12.1 (7.6-20.0)
EuroSCORE II, % 4.2 (2.6-7.4)
STS score, % 4.4 (2.7-7.0)
NYHA functional class III/IV 167 (66.8)
COPD 31 (12.4)
Diabetes mellitus 72 (28.8)
GFR ml/min 52.4  22.1
Extracardiac arteriopathy 70 (28.0)
Peripheral vascular disease 36 (14.4)
Previous stroke, major/minor 23 (9.2)
Previous pacemaker 24 (9.6)
Coronary artery disease 170 (68.0)
Previous myocardial infarction 23 (9.2)
Previous PCI 102 (40.8)
Previous CABG 15 (6.0)
Echocardiographic characteristics
LVEF <35% 31 (12.4)
AR IIIþ 3 (1.2)
MR IIIþ 8 (3.2)
Electrocardiographic characteristics
Atrial ﬁbrillation 75 (30.0)
RBBB 19 (7.6)
LBBB 7 (2.8)
Values are mean  SD, n (%), or median (interquartile range).
AR ¼ aortic regurgitation; BMI ¼ body mass index; CABG ¼ coronary artery
bypass graft; COPD ¼ chronic obstructive pulmonary disease; EuroSCORE ¼
European System for Cardiac Operative Risk Evaluation GFR ¼ glomerular ﬁltration
rate; LBBB ¼ left bundle branch block; LVEF ¼ left ventricular ejection fraction;
MR ¼ mitral regurgitation; NYHA ¼ New York Heart Association; PCI ¼ percuta-
neous coronary intervention; RBBB ¼ right bundle branch block; STS ¼ Society of
Thoracic Surgeons.
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1811using previously described techniques, by either
calculation from the MSCT (15) or the combination of
angiographic and ﬂuoroscopic guidance (16). A pigtail
was placed in the right coronary cusp, and an
orthogonal view of the 3 aortic cusps was conﬁrmed
by aortic angiography. Initially, the center dot was
placed at the middle of the virtual annulus, and the
valve was expanded under rapid pacing. With
growing experience, to avoid excessively deep im-
plantation of the prosthesis within the left ventricular
outﬂow tract, this strategy was changed to a higher
position of the center dot in relation to the virtual
annulus plane.
Post-dilation was performed if paravalvular
leakage was evident on post-deployment angiog-
raphy and/or transesophageal echocardiography or if
ﬂuoroscopy revealed prosthesis underexpansion
using the delivery system’s balloon and adding w1 to
2 ml to the recommended ﬁlling volume at the
operator’s discretion.
DEFINITION OF ENDPOINTS AND FOLLOW-UP.
All data up to 30 days were prospectively collected
during routine ambulatory visits at the outpatient
clinic, by referring to the treating physician, and
other hospital documentation or the patient directly.
All clinical endpoints, procedural success, and the
composite early safety endpoint at 30 days were
categorized using VARC-2 criteria (13). In brief, device
success was deﬁned as the absence of procedural
mortality, correct positioning of a single prosthetic
heart valve in the proper anatomic location, and
intended performance. The occurrence of all-cause
mortality, stroke, rehospitalization for worsening
heart failure, vascular complications, bleeding, acute
kidney injury, myocardial infarction, valve-related
dysfunction, and endocarditis or valve thrombosis
up to 30 days was assessed. The incidence of per-
manent pacemaker implantation was recorded. The
composite endpoint early safety at 30 days (all-cause
mortality, stroke [disabling and nondisabling], life-
threatening bleeding, acute kidney injury (RIFLE
[Risk, Injury, Failure, Loss, and End-stage kidney
disease] 2 or 3 or renal replacement therapy), coro-
nary artery obstruction requiring intervention, major
vascular complication, and valve-related dysfunction
requiring repeat procedure) was evaluated.
STATISTICAL ANALYSIS. Continuous variables are
expressed as mean with the SD or the median with the
interquartile range. A repeated-measures analysis of
variance with the post hoc Bonferroni correction was
used for within-patient repeated measures of mean
transaortic gradient at baseline, after TAVR and at
30 days. McNemar test for correlated categorical datawas used to compare the proportions of patients in
New York Heart Association (NYHA) functional class
III/IV at baseline and 30 days. A 2-sided p value <0.05
was considered statistically signiﬁcant for all anal-
yses. IBM SPSS Statistics version 22 (IBM, Armonk,
New York) was used for all analyses.
RESULTS
PATIENT CHARACTERISTICS. In total, 250 patients
undergoing transfemoral TAVR with the S3 THV were
analyzed. Their mean age was 81.0  6.2 years, and
43.6% were female. Baseline characteristics of the
entire patient population are listed in Table 1. The risk
proﬁle included an elevated burden of comorbidities
resulting in an intermediate-risk population (median
logistic EuroSCORE [European System for Cardiac
Operative Risk Evaluation] I: 12.1%, EuroSCORE II:
4.2%, and Society of Thoracic Surgeons score: 4.4%).
Left ventricular ejection fraction was severely
TABLE 3 MSCT-Derived Aortic Annular Anatomy and Degree of
Oversizing (N ¼ 248*)
Minimal diameter, mm 21.1  2.4
Maximal diameter, mm 27.1  2.7
Effective diameter, mm 24.1  2.4
Perimeter, mm 77.4  7.5
Area, cm2 4.7  0.9
Prosthesis oversizing by area, % 7.2 (0.4 to 13.9)
Eccentricity index 0.2  0.1
Degree of calciﬁcation (0–3)
Cusps, moderate/severe 176 (70.4)
Annulus, moderate/severe 25 (10.0)
LVOT, moderate/severe 17 (6.8)
Values are mean  SD, median (interquartile range), or n (%). *Excluding patients
without MSCT.
LVOT¼ left ventricular outﬂow tract; MSCT¼multislice computed tomography.
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1812depressed (<35%) in 12.4% (31 of 250) of the patients.
A previous pacemaker was present in 9.6% (24 of 250)
of the patients. The median stay in the intensive care
unit and the stay in hospital were 1.0 (1.0 to 2.0) and
5.0 (5.0 to 7.0) days, respectively.
PROCEDURAL CHARACTERISTICS AND PROSTHESIS
SIZING. All patients underwent TAVR using the
transfemoral access. Conscious sedation was used in
43.6% (109 of 250) of the patients. The 23-, 26-, and
29-mm S3 THVs were used in 42.8%, 37.2%, and
20.0% of the patients, respectively. Procedural char-
acteristics are shown in Table 2. MSCT measurements
of the aortic annulus are presented in Table 3. Mea-
surements were evaluated for 248 patients because
1 patient did not undergo MSCT due to renal failure
and 1 patient had not previously undergone MSCT.
The mean aortic annular area was 4.7  0.9 cm2,
resulting in a median prosthesis oversizing by area of
7.2% (interquartile range: 0.4% to 13.9%). Prosthesis
sizing was within the manufacturer’s recommended
range in 77.4%, undersized in 12.1%, and oversized in
10.5% of the patients. Post-dilation was performed in
34.4% (86 of 250).
VARC-2–DEFINED DEVICE SUCCESS AND IN-HOSPITAL
OUTCOME. VARC-2–deﬁned device success was
achieved in 97.6% (244 of 250) of the patients
(Table 4). No intraprocedural death occurred. There
was no post-implantation paravalvular leakage inTABLE 2 Procedural Characteristics: Total Patients (N ¼ 250)
Prosthesis size, mm
23 107 (42.8)
26 93 (37.2)
29 50 (20.0)
Conscious sedation 109 (43.6)
ECMO
Prophylactic 2 (0.8)
Emergency 1 (0.4)
Pre-dilation 246 (98.4)
Standard balloon* 175 (70.0)
Other balloon 71 (28.4)
Post-dilation† 86 (34.4)
Procedural time, min 59.9  22.9
Fluoroscopy time, min 13.4  5.7
Contrast, ml 113.9  62.6
Days in hospital 5.0 (5.0–7.0)
Days in the intensive care unit 1.0 (1.0–2.0)
Values are n (%), mean  SD, or median (interquartile range). *Balloon with the
recommended volume included with the delivery system and transcatheter heart
valve (THV) (i.e., 20-mm balloon for 23-mm THV, 23-mm for 26-mm THV, and
25-mm for 29 mm-THV). †Post-dilation was performed using the delivery system’s
balloon and adding w1 to 2 ml to the recommended ﬁlling volume at the
operator’s discretion.
ECMO ¼ extracorporeal membrane oxygenation.56.4%, and it was mild in 41.6% and moderate in 2.0%
of patients. No patient had severe paravalvular
leakage. Intended prosthesis performance was not
achieved in 5 patients (2.0%) due to residual para-
valvular leakage more than grade II, and 1 patient
required a second valve due to severe paravalvular
leakage after the ﬁrst valve implantation.
In-hospital outcome and complications are given in
Table 5. No in-hospital death occurred. The stroke
rate was 2.8% (7 of 250), with disabling strokes in
3 patients. Life-threatening bleeding and major
vascular complications occurred in 4.4% (11 of 250)
and 3.6% (9 of 250) of the patients, respectively. A
new permanent pacemaker implantation was re-
quired in 35 patients (14.0%). Excluding patients with
a permanent pacemaker at baseline, the incidence of
new pacemaker implantation was 15.5% (25 of 226).
No myocardial infarction occurred. Acute kidney
injury (deﬁned as RIFLE 2/3) occurred in 2.0%
(5 of 250). Postprocedural echocardiography showed a
signiﬁcant decrease in mean transvalvular gradient
(43.3  15.2 mm Hg to 12.1  5.1 mm Hg; p < 0.0001)
(Figure 1).TABLE 4 VARC-2–Deﬁned Device Success (N ¼ 250)
Device success 244 (97.6)
Procedural mortality 0 (0)
Intended performance* 245 (98.0)
Multiple valves 1 (0.4)
Correct position of the device in the
proper anatomical location
250 (100)
Successful vascular access, delivery,
and deployment of the device and
successful retrieval of the delivery system
249 (99.6)
Values are n (%). *No prosthesis mismatch, mean aortic valve gradient
<20 mm Hg or peak velocity <3 m/s, without moderate or severe prosthetic valve
aortic regurgitation.
TABLE 5 Clinical Outcome In-Hospital and at 30 Days
In-Hospital Events
(N ¼ 250)
At 30 Days*
(N ¼ 250)
Mortality
All-cause mortality 0 (0) 1 (0.4)
Noncardiac mortality 0 (0) 1 (0.4)
Cardiac mortality 0 (0) 0 (0)
Neurological complications
All stroke 7 (2.8) 8 (3.2)
Disabling stroke 3 (1.2) 4 (1.6)
Nondisabling stroke 4 (1.6) 4 (1.6)
TIA 1 (0.4) 1 (0.4)
Hospitalization for valve-related
symptoms or worsened CHF
— 5 (2.0)
Major vascular complication 9 (3.6) 9 (3.6)
Life-threatening bleeding 11 (4.4) 12 (4.8)
AKI 2/3, including renal
replacement therapy
5 (2.0) 5 (2.0)
Coronary artery obstruction
requiring intervention
0 (0) 0 (0)
Myocardial infarction 0 (0) 0 (0)
Valve-related dysfunction
requiring repeat procedure
(BAV, TAVR, or SAVR)
0 (0) 0 (0)
Endocarditis 0 (0) 0 (0)
Valve thrombosis 0 (0) 0 (0)
NYHA functional class III/IV — 17 (6.8)
New pacemaker† 35 (14.0) 38 (15.2)
VARC-2 early safety composite
endpoint at 30 days
— 25 (10.0)
Values are n (%). *Events after hospital discharge until 30 days not available for
1 patient who was lost to follow-up due to inability to contact. †Percentage given
for the entire cohort as the denominator; new pacemaker rate in hospital and at
30 days in patients without a previous pacemaker was 15.5% (35 of 226) and
16.8% (38 of 226), respectively.
AKI ¼ acute kidney injury; BAV ¼ balloon aortic valvuloplasty; CHF ¼ congestive
heart failure; NYHA ¼ New York Heart Association; SAVR ¼ surgical aortic valve
replacement; TAVR ¼ transcatheter aortic valve replacement; TIA ¼ transient
ischemic attack; VARC ¼ Valve Academic Research Consortium.
FIGURE 1 Mean Transvalvular Gradient at Baseline, Discharge, and 30 Days
Mean transvalvular gradient at baseline, discharge, and 30 days in 185 patients with
complete echocardiographic data showing a signiﬁcant improvement in the mean trans-
valvular gradient after transcatheter aortic valve replacement and at 30 days.
FIGURE 2 NYHA Functional Class at Baseline and at 30 Ddays
New York Heart Association (NYHA) functional class at baseline and discharge for
250 patients with complete follow-up at 30 days.
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Follow-up at 30 days was complete in 249 patients.
One patient was lost to follow-up due to inability
to contact. The 30-day event-free rate was 90.0%
(225 of 250), with the composite early safety endpoint
observed in 10.0% (25 of 250) (Table 5). From hospital
discharge to 30 days, 1 case of disabling stroke, 1 case
of life-threatening bleeding, and 3 permanent pace-
maker implantations were observed, resulting in a
30-day event rate of 3.2% (8 of 250), 4.8% (12 of 250),
and 15.2% (38 of 250), respectively. No major vascular
complication, myocardial infarction, endocarditis, or
valve thrombosis was recorded from discharge to
30 days. One patient (0.4%) died of sepsis with mul-
tiorgan failure.
Patients’ symptoms markedly ameliorated with an
improvement in NYHA functional class in 89.2%
of the patients (Figure 2). Using the McNemar test,
there was a statistically signiﬁcant difference in theproportion of patients in NYHA functional class III/IV
before and after TAVR (66.8% [167 of 250] vs. 6.8% [17
of 250]; p < 0.001). Of the patients who were hospi-
talized for worsening heart failure within 30 days
(2.0%, 5 of 250), all showed NYHA functional class
lower than III at the 30-day visit. Echocardiographic
data at 30 days were available for 185 patients. Mean
gradient was stable from discharge examination to
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0.023) (Figure 1).
DISCUSSION
We report our initial experience of in-hospital and
30-day event rates according to VARC-2 in a medium-
sized patient population using a novel balloon-
expandable THV. We found excellent outcomes
using the S3 THV with very low mortality and high
device success rates. With the ﬁnal PARTNER II S3
results pending, our study may be of interest to cli-
nicians using this novel device.
VARC-2–DEFINED EARLY SAFETY AT 30 DAYS AND
DEVICE SUCCESS. The main ﬁnding of this single-
center observational study is the high rate of VARC-
2–deﬁned device success (97.6%) and freedom of the
composite VARC-2–deﬁned early safety endpoint at
30 days of 90.0% with an all-cause mortality rate
of <1%. The VARC-2–deﬁned composite endpoint
early safety at 30 days summarizes important
measures of complications and mortality and has
been proposed for assessment of patient safety in
TAVR. Two recent meta-analyses have reported
freedom from VARC-2–deﬁned early safety com-
posite endpoint at 30 days in w77% of the cases
(17,18). Compared with these data, in the present
intermediate-risk population, we observed freedom
of this composite endpoint in 90% after 30 days,
indicating an excellent safety proﬁle of this novel
device.
Device success is a composite endpoint especially
driven by the presence of residual moderate or severe
paravalvular leakage, showing an incidence of 12% to
24% in the literature (19). As emerging evidence in-
dicates a strong inﬂuence of paravalvular leakage on
long-term mortality (17,20), much effort has been
undertaken to develop techniques to reduce its inci-
dence in the development of new THVs. The S3 fea-
tures a sealing skirt at its lower portion and a more
accurate positioning mechanism and thus may pro-
vide a better prevention of paravalvular leaks. With
moderate or severe paravalvular leakage of 2.0% in
this study, and 0 to 3.8% in other studies (8,10,11),
hemodynamic results of the S3 THV seem superior
compared with older THV and comparable to other
newer generation devices such as the Direct
Flow Medical (21) or the Lotus THV (22). Although
the occurrence of paravalvular leakage is probably
multifactorial, in the case of moderate paravalvular
leakage in our population, the most likely reasons
were a slightly high position of the valve (n ¼ 3), heavy
calciﬁcation (n ¼ 1), and selection of the smallerprosthesis in borderline ranges with no improvement
after postdilation (1 patient).
In the present series, post-dilation was performed
in 34.4% of the patients. Other series report post-
dilation rates of 1% to 4%. Unpublished results from
the PARTNER II S3 program (12) have reported a post-
dilation rate between 11% and 15%. The underlying
reasons for the observed elevated post-dilation rate
in our series compared with other groups remain
unclear; however, using this strategy we were able to
achieve excellent procedural results and outcome at
30 days.
VASCULAR COMPLICATIONS AND BLEEDING.
Vascular complications after TAVR are a frequent
complication and the main determinant of bleeding
and mortality (23,24). Previous devices, requiring
larger sheaths (24- to 26-F inner diameter), showed an
incidence of major vascular complications ranging
from 5% to 23% (18). With increasing experience and
evolution of TAVR systems, this ﬁgure has consider-
ably decreased to w16% (3). Major vascular compli-
cations and life-threatening bleeding with the novel
low-proﬁle S3 THV (14- to 16-F inner diameter)
range between 0 and 5.9% and 0 and 5.4%, respec-
tively (8,10–12). In the present study, we observed
comparable rates with major vascular complications
in 3.6% and life-threatening bleeding in 4.8% of
patients.
STROKE. New cerebrovascular events after TAVR are
frequent but are silent in most cases. The incidence of
30-day clinically apparent major or disabling stroke is
in the range of w2% to 4% (25–28) and seems to be
independent of valve type and access (27). We
observed a rate of disabling stroke of 1.6%, comparing
favorably with these previous data being at the lower
limit of the expected. Other groups, treating patients
with a transfemoral S3 THV, have reported similar
stroke rates ranging from 0 to 2% (8,10–12).
NEW PERMANENT PACEMAKER IMPLANTATIONS.
The incidence of new permanent pacemaker implan-
tations after TAVR using balloon-expandable valves
ranges between 5% and 12% (1,29,30). Although the
impact on clinical outcome remains controversial, no
impact on survival has been observed (31,32). How-
ever, new permanent pacemakers may limit clinical
beneﬁt due to the loss of atrioventricular synchrony
and right ventricular pacing (33) and procedural costs
may increase (34).
Preliminary studies have reported new permanent
pacemakers after TAVR with the S3 THV in 13% to
25.5% (9–11). In the yet unpublished PARTNER II S3
program, the new permanent pacemaker rate in the
PERSPECTIVES
WHAT IS KNOWN? To date, only data from small series and
1 modest-sized multicenter study on the novel SAPIEN 3 trans-
catheter heart valve are available, and clinical efﬁcacy and
30-day outcome are still unclear.
WHAT IS NEW? In this medium-size single-center observa-
tional study, we found excellent 30-day outcomes with very low
rates of clinical adverse events according to the VARC-2 com-
posite early safety endpoint with the SAPIEN 3. In a real-world
experience outside of trial constraints, high rates of device suc-
cess could be achieved. However, the need for new pacemaker
implantation appears to be slightly increased.
WHAT IS NEXT? Conﬁrmation of these excellent short-term
outcomes and maintenance in the long term are warranted.
The underlying mechanisms of new permanent pacemaker
implantations merit further research.
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1815entire transfemoral intermediate-risk cohort was
10.4% (12). We observed a 30-day rate of new per-
manent pacemaker in 15.2% of the entire cohort and
in 16.8% of the patients without a previous pace-
maker at 30 days. The development of novel devices
should weigh potential improvements, such as mini-
mizing paravalvular leakage and vascular complica-
tions, against an increase in new permanent
pacemaker implantations and new-onset conduction
abnormalities. Minimizing these complications is
mandatory for further application of TAVR, especially
in intermediate-risk patients. The potential de-
terminants of new permanent pacemaker implanta-
tions and conduction abnormalities include the high
frame of the S3 THV and the deeper extension into
the left ventricular outﬂow tract (7). Depth of im-
plantation has already been shown to be associated
with pacemaker implantation after TAVR with the S3
THV (9). However, the learning curve may play a role,
and the appropriateness of manufacturer’s sizing
recommendations may require critical appraisal.
Further research to identify the determinants of new
conduction abnormalities is warranted to potentially
reduce permanent pacemaker implantations using
this novel device.
STUDY LIMITATIONS. This was an observational
study from a single center without center-independent
adjudication of post-procedural results and the lack
of independent core lab assessment of paravalvular
leakage on echocardiography.
CONCLUSIONS
We report our ﬁrst experience using a novel balloon-
expandable THV redesigned to minimize residual
paravalvular leakage and with low-proﬁle sheaths.The main ﬁnding of this single-center observational
study is the high device success rate of 97.6%,
freedom of VARC-2–deﬁned early safety composite
endpoint in 90%, and a 30-day all-cause mortality
rate <1%. In addition to these promising clinical re-
sults, we observed an increased rate of new perma-
nent pacemaker implantations.
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